Three Health Care Stocks That Could Revitalize Your Portfolio This November
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Should l Buy ACHC?
Source: Benzinga
Oversold Stocks Opportunity: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Alvotech SA Update: Alvotech's stock dropped 41% over the past month following an FDA Complete Response Letter regarding its AVT05 biosimilar application, with an RSI of 18.8 and a closing price of $5.03.
Acadia Healthcare Performance: Acadia Healthcare's stock fell 19% in the last month, with an RSI of 27.9, and it closed at $21.31 ahead of its third-quarter results announcement.
Akebia Therapeutics Decline: Akebia Therapeutics experienced a 33% drop in stock price over five days, with an RSI of 29.4, closing at $2.12 after reporting inducement grants.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACHC
Wall Street analysts forecast ACHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACHC is 19.55 USD with a low forecast of 13.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
6 Buy
4 Hold
1 Sell
Moderate Buy
Current: 13.430
Low
13.00
Averages
19.55
High
27.00
Current: 13.430
Low
13.00
Averages
19.55
High
27.00
About ACHC
Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services across the United States. It provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics. Its acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. Its specialty treatment facilities include residential recovery facilities and eating disorder facilities. Its comprehensive treatment centers specialize in providing medication-assisted treatment in an outpatient setting. Its residential treatment centers treat patients with behavioral disorders in a non-hospital setting. The facilities balance therapy activities with social, academic and other activities. It operates a network of 262 behavioral healthcare facilities with over 11,850 beds in 39 states and Puerto Rico.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acadia Healthcare to Release Q4 and Year-End 2025 Results
- Earnings Release Schedule: Acadia Healthcare announced it will release its Q4 and year-end 2025 results on February 25, 2026, before market open, reflecting the company's commitment to transparency and investor communication.
- Investor Conference Call: On the same day, Acadia will hold a conference call at 9:00 a.m. ET to engage with institutional investors and analysts, aiming to enhance market confidence.
- Network Coverage: As of September 30, 2025, Acadia operates 278 behavioral healthcare facilities across the U.S. and Puerto Rico, providing approximately 12,500 beds, showcasing its leadership in the industry.
- Employee and Patient Services: With around 25,500 employees serving over 82,000 patients daily, Acadia solidifies its position as the largest stand-alone behavioral healthcare company in the U.S.
See More
Trump Threatens Tariffs, Market Drops 1.5% Amid Risk-Off Sentiment
- Market Reaction: The S&P 500 fell 1.5% to 6,840 points due to Trump's aggressive trade stance towards Europe, marking its worst session since late November, primarily dragged down by consumer discretionary and technology stocks.
- Tariff Threats: Trump threatened to impose a 10% tariff on several European countries starting February 1 if negotiations over Greenland control fail, with potential increases to 25% by June, which could impact up to 25% of U.S. exports to Europe, leading to cautious market reactions.
- Fixed Income Volatility: Long-dated Treasury yields climbed to their highest levels since late September, with the 30-year yield rising 6 basis points to 4.90%, reflecting a risk-off sentiment among investors.
- Precious Metals Surge: Safe-haven demand pushed gold prices up 1.9% to $4,760 per ounce and silver nearly 5% to $94.50 per ounce, indicating market concerns over economic uncertainty.
See More
Acadia Healthcare Appoints Debra K. Osteen as CEO, Stock Surges 21.49%
- Executive Transition: Debra K. Osteen has been appointed as CEO of Acadia effective immediately, succeeding Chris Hunter who stepped down from the Board, indicating a significant leadership change that may influence future strategic directions.
- Financial Guidance Reaffirmed: Acadia reiterated its revenue guidance for 2025 at $3.28 billion to $3.30 billion and adjusted EPS guidance of $1.94 to $2.04, demonstrating the company's confidence in its future performance, which may attract more investor interest.
- Positive Market Reaction: Following the executive transition announcement, Acadia's stock surged 21.49% to $14.20, reflecting market optimism regarding the new leadership and potentially enhancing the company's competitive position.
- Historical Performance Review: For the fiscal year 2024, Acadia reported total revenue of $3.15 billion, indicating stable growth over the past year, and with the new CEO at the helm, further business expansion is anticipated.
See More
Acadia Healthcare Appoints Debra Osteen as CEO, Reaffirms 2025 Financial Guidance
- Executive Change: Acadia Healthcare has appointed Debra Osteen as the new CEO and board member, succeeding Chris Hunter, aiming to enhance operational efficiency through leadership stability amid ongoing industry challenges.
- Financial Guidance Reaffirmed: The company reaffirmed its 2025 financial guidance, projecting revenue between $3.28 billion and $3.30 billion, with adjusted EBITDA expected to be between $601 million and $611 million, indicating confidence in future performance despite cautious market sentiment.
- Earnings Per Share Outlook: Acadia anticipates adjusted earnings per share in the range of $1.94 to $2.04, slightly below the market estimate of $2.05, which may impact investor confidence and exert downward pressure on the stock price.
- Market Reaction: Following the financial guidance announcement, Acadia Healthcare's stock dropped in after-hours trading, reflecting investor concerns about the company's growth potential, particularly in light of structural issues facing the industry.
See More
Acadia Healthcare (ACHC) Announces CEO Change, Debra Osteen Appointed
- Executive Change: Acadia Healthcare announced the immediate resignation of CEO Christopher Hunter, with Debra Osteen appointed as the new CEO, indicating a significant leadership shift that may impact future strategic direction.
- New CEO Background: Prior to joining Acadia, Osteen served as Executive Vice President at Universal Health Services and President of its behavioral health division, and her extensive industry experience is expected to drive Acadia's business growth and market competitiveness.
- Market Reaction: Following the announcement, Acadia's stock price rose by 2.83% in pre-market trading on Nasdaq, reaching $12.01 per share, reflecting investor optimism regarding the new leadership.
- Strategic Implications: This CEO transition may introduce new strategic perspectives and business models, as Acadia needs to adapt to market demands in the rapidly evolving healthcare sector to maintain its competitive edge.
See More
Acadia Healthcare (ACHC) Sees Significant Options Market Volatility
- Options Market Volatility: Acadia Healthcare's March 20, 2026, $22.50 put option shows high implied volatility, indicating that the market expects significant price movement, potentially linked to an upcoming event that could impact investor sentiment.
- Earnings Downgrade: Over the past 60 days, analysts have lowered their earnings estimates for Acadia from $0.67 to $0.10 per share, reflecting a pessimistic outlook on the company's future performance, which may pressure the stock price.
- Zacks Rating: Acadia is rated Zacks Rank #5 (Strong Sell) in the Medical - Hospital industry, which ranks in the top 39% of Zacks Industry Rank, highlighting concerns about its fundamentals in the market.
- Trading Strategy: The high implied volatility of options attracts traders who may employ a selling strategy to capture time decay, indicating uncertainty in the market regarding Acadia's future direction.
See More
Acadia Healthcare to Release Q4 and Year-End 2025 Results
- Earnings Release Schedule: Acadia Healthcare announced it will release its Q4 and year-end 2025 results on February 25, 2026, before market open, reflecting the company's commitment to transparency and investor communication.
- Investor Conference Call: On the same day, Acadia will hold a conference call at 9:00 a.m. ET to engage with institutional investors and analysts, aiming to enhance market confidence.
- Network Coverage: As of September 30, 2025, Acadia operates 278 behavioral healthcare facilities across the U.S. and Puerto Rico, providing approximately 12,500 beds, showcasing its leadership in the industry.
- Employee and Patient Services: With around 25,500 employees serving over 82,000 patients daily, Acadia solidifies its position as the largest stand-alone behavioral healthcare company in the U.S.
See More
Trump Threatens Tariffs, Market Drops 1.5% Amid Risk-Off Sentiment
- Market Reaction: The S&P 500 fell 1.5% to 6,840 points due to Trump's aggressive trade stance towards Europe, marking its worst session since late November, primarily dragged down by consumer discretionary and technology stocks.
- Tariff Threats: Trump threatened to impose a 10% tariff on several European countries starting February 1 if negotiations over Greenland control fail, with potential increases to 25% by June, which could impact up to 25% of U.S. exports to Europe, leading to cautious market reactions.
- Fixed Income Volatility: Long-dated Treasury yields climbed to their highest levels since late September, with the 30-year yield rising 6 basis points to 4.90%, reflecting a risk-off sentiment among investors.
- Precious Metals Surge: Safe-haven demand pushed gold prices up 1.9% to $4,760 per ounce and silver nearly 5% to $94.50 per ounce, indicating market concerns over economic uncertainty.
See More
Acadia Healthcare Appoints Debra K. Osteen as CEO, Stock Surges 21.49%
- Executive Transition: Debra K. Osteen has been appointed as CEO of Acadia effective immediately, succeeding Chris Hunter who stepped down from the Board, indicating a significant leadership change that may influence future strategic directions.
- Financial Guidance Reaffirmed: Acadia reiterated its revenue guidance for 2025 at $3.28 billion to $3.30 billion and adjusted EPS guidance of $1.94 to $2.04, demonstrating the company's confidence in its future performance, which may attract more investor interest.
- Positive Market Reaction: Following the executive transition announcement, Acadia's stock surged 21.49% to $14.20, reflecting market optimism regarding the new leadership and potentially enhancing the company's competitive position.
- Historical Performance Review: For the fiscal year 2024, Acadia reported total revenue of $3.15 billion, indicating stable growth over the past year, and with the new CEO at the helm, further business expansion is anticipated.
See More
Acadia Healthcare Appoints Debra Osteen as CEO, Reaffirms 2025 Financial Guidance
- Executive Change: Acadia Healthcare has appointed Debra Osteen as the new CEO and board member, succeeding Chris Hunter, aiming to enhance operational efficiency through leadership stability amid ongoing industry challenges.
- Financial Guidance Reaffirmed: The company reaffirmed its 2025 financial guidance, projecting revenue between $3.28 billion and $3.30 billion, with adjusted EBITDA expected to be between $601 million and $611 million, indicating confidence in future performance despite cautious market sentiment.
- Earnings Per Share Outlook: Acadia anticipates adjusted earnings per share in the range of $1.94 to $2.04, slightly below the market estimate of $2.05, which may impact investor confidence and exert downward pressure on the stock price.
- Market Reaction: Following the financial guidance announcement, Acadia Healthcare's stock dropped in after-hours trading, reflecting investor concerns about the company's growth potential, particularly in light of structural issues facing the industry.
See More
Acadia Healthcare (ACHC) Announces CEO Change, Debra Osteen Appointed
- Executive Change: Acadia Healthcare announced the immediate resignation of CEO Christopher Hunter, with Debra Osteen appointed as the new CEO, indicating a significant leadership shift that may impact future strategic direction.
- New CEO Background: Prior to joining Acadia, Osteen served as Executive Vice President at Universal Health Services and President of its behavioral health division, and her extensive industry experience is expected to drive Acadia's business growth and market competitiveness.
- Market Reaction: Following the announcement, Acadia's stock price rose by 2.83% in pre-market trading on Nasdaq, reaching $12.01 per share, reflecting investor optimism regarding the new leadership.
- Strategic Implications: This CEO transition may introduce new strategic perspectives and business models, as Acadia needs to adapt to market demands in the rapidly evolving healthcare sector to maintain its competitive edge.
See More
Acadia Healthcare (ACHC) Sees Significant Options Market Volatility
- Options Market Volatility: Acadia Healthcare's March 20, 2026, $22.50 put option shows high implied volatility, indicating that the market expects significant price movement, potentially linked to an upcoming event that could impact investor sentiment.
- Earnings Downgrade: Over the past 60 days, analysts have lowered their earnings estimates for Acadia from $0.67 to $0.10 per share, reflecting a pessimistic outlook on the company's future performance, which may pressure the stock price.
- Zacks Rating: Acadia is rated Zacks Rank #5 (Strong Sell) in the Medical - Hospital industry, which ranks in the top 39% of Zacks Industry Rank, highlighting concerns about its fundamentals in the market.
- Trading Strategy: The high implied volatility of options attracts traders who may employ a selling strategy to capture time decay, indicating uncertainty in the market regarding Acadia's future direction.
See More
